Last reviewed · How we verify

Regular bupivacaine

Vanderbilt University Medical Center · FDA-approved active Small molecule Under review Quality 0/100

Regular bupivacaine is a Local anesthetic Small molecule drug developed by Vanderbilt University Medical Center. It is currently FDA-approved for Local and regional anesthesia for surgical procedures, Infiltration anesthesia, Nerve blocks. Also known as: Bupivacaine HCl.

Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of nerve impulses.

Regular bupivacaine is a small molecule that acts as a sodium channel protein type IV alpha subunit blocker. It is used to treat various conditions, including postoperative pain, PONV, and Caesarean Section complications, among others.

At a glance

Generic nameRegular bupivacaine
Also known asBupivacaine HCl
SponsorVanderbilt University Medical Center
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Bupivacaine reversibly binds to and inactivates voltage-gated sodium channels on the inner surface of nerve cell membranes, thereby preventing depolarization and action potential generation. This blocks conduction of sensory, motor, and autonomic nerve impulses in a dose-dependent manner. The drug is long-acting due to its high lipophilicity and protein binding, allowing sustained local anesthetic effect.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Regular bupivacaine

What is Regular bupivacaine?

Regular bupivacaine is a Local anesthetic drug developed by Vanderbilt University Medical Center, indicated for Local and regional anesthesia for surgical procedures, Infiltration anesthesia, Nerve blocks.

How does Regular bupivacaine work?

Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of nerve impulses.

What is Regular bupivacaine used for?

Regular bupivacaine is indicated for Local and regional anesthesia for surgical procedures, Infiltration anesthesia, Nerve blocks, Epidural anesthesia, Spinal anesthesia.

Who makes Regular bupivacaine?

Regular bupivacaine is developed and marketed by Vanderbilt University Medical Center (see full Vanderbilt University Medical Center pipeline at /company/vanderbilt-university-medical-center).

Is Regular bupivacaine also known as anything else?

Regular bupivacaine is also known as Bupivacaine HCl.

What drug class is Regular bupivacaine in?

Regular bupivacaine belongs to the Local anesthetic class. See all Local anesthetic drugs at /class/local-anesthetic.

What development phase is Regular bupivacaine in?

Regular bupivacaine is FDA-approved (marketed).

What are the side effects of Regular bupivacaine?

Common side effects of Regular bupivacaine include Hypotension, Bradycardia, Dizziness, Headache, Systemic toxicity (CNS and cardiac effects at high doses), Allergic reactions.

What does Regular bupivacaine target?

Regular bupivacaine targets Voltage-gated sodium channels and is a Local anesthetic.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing